Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders

, lymphangioleiomyomatosis, plastic bronchitis, lymphadenopathy caused by rheumatoid arthritis, etc.

  • 0 views
  • 24 Feb, 2020
  • 1 location
Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the treatment of subjects with untreated angioimmunoblastic T cell lymphoma.

doxorubicin
measurable disease
t-cell lymphoma
cyclophosphamide
prednisone
  • 0 views
  • 15 Mar, 2020
Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone Etoposide and Thalidomide)

This study aims to investigate the efficacy and safety of PET regimen combined with Chidamide for angioimmunoblastic T cell lymphoma patients.

neutrophil count
prednisone
t-cell lymphoma
thalidomide
platelet count
  • 0 views
  • 08 Nov, 2020
  • 1 location
A Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy

advanced metastases. No specific treatment modality has been established as the standard therapy. Systemic therapy is usually considered since lymphadenopathy is considered as a sign of disease

  • 6 views
  • 08 Nov, 2020
  • 1 location
Feasability Study on the Contribution of Guided Puncture With Echoendoscopy

Impact of screening nodes mediastinal by PET, at different times of the management of cancer disease, remain unclear. Benefits of combined PET and puncture with echoendoscopy for the diagnosis subsequent therapeutic management should be evaluated in these different contexts. We would like to demonstrate the clinical utility of this association …

  • 0 views
  • 08 Nov, 2020
Individualized Precise Radiotherapy With the Guidance of Radiosensitivity of Locally Advanced Cervical Cancer

with FIGO stages IB2-IVA and had no para-aortic lymphadenopathy (>10 mm) assessed by PET-CT or MRI. All the patients received definitive radiotherapy consisting of external beam whole pelvic RT

iia2
fludeoxyglucose f 18
chemoradiotherapy
squamous cell carcinoma
treatment regimen
  • 7 views
  • 08 Nov, 2020
  • 1 location
Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

To assess the clinical activity of nivolumab monotherapy, as measured by the investigator-assessed clinical benefit rate (CBR), in patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors (GCT). CBR is defined by sum of complete responses (CR), partial responses (PR) and stable disease (SD) for at least 3 months, with …

primary tumor
testicular
progressive disease
seminoma
luteinizing hormone
  • 19 views
  • 08 Nov, 2020
  • 1 location
Ilaris (Canakinumab) in Patient With Periodic Fever Aphthous Stomatitis Pharyngitis and Cervical Adenitis (PFAPA)

Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis (PFAPA) is one of the most common, least explored periodic fever syndrome in childhood. This study aims to investigate whether a single dose of an interleukin beta (IL-1) antagonist, Canakinumab will be able to abort PFAPA flares in patients who experience a …

  • 21 views
  • 08 Nov, 2020
  • 1 location
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

extranodal nk/t-cell lymphoma, nasal type
lymphoma
burkitt's lymphoma
hodgkin's disease
treatment regimen
  • 87 views
  • 08 Jan, 2021
  • 2 locations
Study of Efficacy of CDZ173 in Patients With APDS/PASLI

This study is designed to explore CDZ173, a selective PI3K inhibitor, in patients with genetically activated PI3K, i.e., patients with APDS/PASLI. The study consists of two parts. Part I is the open label part designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as well as …

  • 0 views
  • 16 Feb, 2020
  • 9 locations